Management Changes at BioGaia
Axel Sjöblad, Managing Director has agreed with the Board of BioGaia AB to end his employment with the company as of June 30th 2018.
Axel Sjöblad was appointed as Managing Director effective March 1, 2016 and has successfully focused on further expanding BioGaias sales capabilities.
”I am proud of the progress that has taken place at the company during my time at BioGaia. Now the company is entering into the next phase with greater focus on consumer marketing and advanced research including the microbiome field. I have therefore agreed with the Board to resign as Managing Director”, says Axel Sjöblad.
The search for a new Managing Director has commenced.
The Board of BioGaia has appointed Sebastian Schröder as Acting Managing Director until such time that a new Managing Director is appointed. Thereafter Sebastian Schröder will take on the position as Executive Vice president Strategy and Business Development.
Sebastian Schröder originally joined BioGaia in 2003 and left the company in 2006 to pursue new challenges. He was recruited back to BioGaia in 2015 to lead the Strategy and Business Development functions.
”We thank Axel Sjöblad for his successful efforts including record sales, geographic expansion and the further introduction of our products in existing markets” says Peter Rothschild, Chairman of BioGaia.
This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 23 May 2018, at 13:00 CET.
Latest press releases from BioGaia
2018-05-22 BioGaia signs exclusive agreement in Mongolia
2018-04-26 Annual General Meeting of BioGaia
2018-04-25 BioGaia AB – Interim management statement 1 January – 31 March 2018
For additional information please contact
Peter Rothschild, Chairman of the board BioGaia, +46 (0)708 306 540
BioGaia is an innovative Swedish healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are sold through local distribution partners in around 100 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. www.biogaia.com